Spyre Therapeutics (SYRE) Accounts Payables (2015 - 2026)
Spyre Therapeutics posted quarterly Accounts Payables of $50000.0 for Q1 2026, down 98.64% year-on-year from $3.7 million in Q1 2025, and up 257.14% on a QoQ basis from $14000.0 in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Accounts Payables data on file, last reported at $50000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables fell 98.64% year-over-year to $50000.0; the trailing twelve-month figure through Mar 2026 stood at $50000.0 (down 98.64% YoY), and the FY2025 full-year result was $14000.0, down 97.68% from the prior year.
- Accounts Payables for Q1 2026 stood at $50000.0, up from $14000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $20.8 million in Q2 2023 and bottomed at $14000.0 in Q4 2025.
- The 5-year median for Accounts Payables is $3.0 million (2022), against an average of $4.3 million.
- The widest annual swing landed in 2023, when Accounts Payables surged 962.82%; it then tumbled 99.04% in 2025.
- A 5-year view of Accounts Payables shows it stood at $677000.0 in 2022, then soared by 32.35% to $896000.0 in 2023, then plunged by 32.7% to $603000.0 in 2024, then tumbled by 97.68% to $14000.0 in 2025, then jumped by 257.14% to $50000.0 in 2026.
- The last three Accounts Payables figures came in at $50000.0 (Q1 2026), $14000.0 (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 50,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 603,000.00 |
| Sep 30, 2024 | 5.17 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 896,000.00 |
| Sep 30, 2023 | 19.82 Mn |
| Jun 30, 2023 | 20.81 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Dec 31, 2022 | 677,000.00 |
| Sep 30, 2022 | 4.18 Mn |
| Jun 30, 2022 | 1.96 Mn |
| Mar 31, 2022 | 2.98 Mn |
| Dec 31, 2021 | 3.32 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Mar 31, 2021 | 1.88 Mn |
| Dec 31, 2020 | 2.25 Mn |
| Sep 30, 2020 | 2.30 Mn |
| Jun 30, 2020 | 4.15 Mn |
| Mar 31, 2020 | 3.62 Mn |
| Dec 31, 2019 | 3.15 Mn |
| Sep 30, 2019 | 2.43 Mn |
| Jun 30, 2019 | 2.72 Mn |
| Mar 31, 2019 | 3.22 Mn |
| Dec 31, 2018 | 663,000.00 |
| Sep 30, 2018 | 1.08 Mn |
| Jun 30, 2018 | 952,000.00 |
| Mar 31, 2018 | 763,000.00 |
| Dec 31, 2017 | 389,000.00 |
| Sep 30, 2017 | 615,000.00 |
| Jun 30, 2017 | 634,000.00 |
| Mar 31, 2017 | 267,000.00 |
| Dec 31, 2016 | 168,000.00 |
| Sep 30, 2016 | 523,000.00 |
| Jun 30, 2016 | 348,000.00 |
| Mar 31, 2016 | 509,000.00 |
| Dec 31, 2015 | 176,000.00 |